Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conversion from calcineurin inhibitors to sirolimus versus continued calcineurin inhibitor therapy in renal allograft recipients
2006-005687-44Phase 3
- Sponsor
- Wyeth
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sirolimus in kidney transplant (2 arms), sponsored by Wyeth. Primary endpoint: Nankivell glomerular filtration rate.
02
Drugs
sirolimus
03
Conditions
kidney transplant
Beyond the preview
Go deeper on 2006-005687-44.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005687-44.